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Abstract  27 
 28 
Rationale: The hallmark of severe influenza virus infections is excessive inflammation of the 29 
lungs. Platelets are activated during influenza, but their role in influenza virus pathogenesis 30 
and inflammatory responses is unknown. 31 
Objectives: To determine the role of platelets during influenza A virus (IAV) infections and 32 
propose new therapeutics against influenza. 33 
Methods: We used targeted gene deletion approaches and pharmacological interventions to 34 
investigate the role of platelets during influenza virus infection in mice. 35 
Measurements and Main Results: Lungs of infected mice were massively infiltrated by 36 
aggregates of activated platelets. Platelet activation promoted IAV pathogenesis. Activating 37 
protease-activated receptor 4 (PAR4), a platelet receptor for thrombin that is crucial for 38 
platelet activation, exacerbated influenza-induced acute lung injury and death. In contrast, 39 
deficiency in the major platelet receptor glycoprotein IIIa (GPIIIa) protected mice from death 40 
caused by influenza viruses, and treating the mice with a specific GPIIbIIIa antagonist, 41 
eptifibatide, had the same effect. Interestingly, mice treated with other anti-platelet 42 
compounds (antagonists of PAR4, MRS 2179, and clopidogrel) were also protected from 43 
severe lung injury and lethal infections induced by several influenza strains. 44 
Conclusions: The intricate relationship between hemostasis and inflammation has major 45 
consequences in influenza virus pathogenesis, and anti-platelet drugs might be explored to 46 
develop new anti-inflammatory treatment against influenza virus infections.  47 
Key words: Lung injury, novel drugs, Flu pathogenesis, pneumonia, platelets.  48 
49 
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Introduction 50 
Influenza is one of the most common infectious diseases in humans, occurring as sporadic 51 
pandemic and seasonal epidemic outbreaks, leading to significant numbers of fatalities. 52 
Influenza pathogenesis is a complex process involving both viral determinants and the 53 
immune system (1-3). During severe influenza, dysregulation of cytokine production 54 
contributes to lung damage, possibly leading to organ failure and death (4-6). The 55 
endothelium, which lines the interior surface of the blood vessels, is thought to orchestrate the 56 
crescendo in cytokine accumulation, although the mechanism involved is not fully understood 57 
(7).  58 
 59 
Upon endothelial injury, platelets are recruited by inflamed endothelial cells, where they 60 
adhere and are activated (8). Simultaneously, the family of protease-activated receptors 61 
(PARs) mediates platelet activation by thrombin. PAR4 is strictly required for platelet 62 
activation in mice, as mouse platelets do not express PAR1. In contrast, both PAR1 and PAR4 63 
are important for platelet activation in humans. These events lead to a conformational change 64 
in the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor for fibrinogen that bridges platelets, 65 
leading to their aggregation and a reinforcement of their activation. Importantly, platelet 66 
activation is strongly associated with enhanced inflammatory responses. Activated platelets 67 
release potent inflammatory molecules and play a key role in leukocyte recruitment (9). 68 
Platelet activation is finely tuned, but its dysfunction is pathogenic and contributes to 69 
inflammatory disorders (10, 11). Thus, uncontrolled platelet activation could contribute to the 70 
pathogenesis of IAV infections by fueling a harmful inflammatory response in the respiratory 71 
tract. However, the role of platelets in the context of IAV infection has never been 72 
investigated. In the present study, using pharmacological and gene deletion approaches, we 73 
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investigated the role of platelets in IAV pathogenesis in vivo. We found that during severe 74 
influenza A virus infection in mice, platelet activation worsens the severity of lung injury.  75 
76 
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METHODS 77 
 78 
Reagents 79 
A549 cells and MDCK cells were purchased from ATCC (Molsheim Cedex, France). IAV 80 
A/PR/8/34 virus (H1N1), A/HK/1/68 (H3N2) and A/NL/602/2009 (H1N1) (ATCC) were gifts 81 
from G.F. Rimmelzwaan (Erasmus, Netherlands). The highly pathogenic avian 82 
A/FPV/Bratislava/79 (H7N7) strain was from the Institute of Molecular Virology, Münster, 83 
Germany. The following reagents were used: DAPI (Life Technologies, Paris, France), Alexa 84 
Fluor® secondary antibodies (Life Technologies), eptifibatide (Integrilin®, GlaxoSmithKline, 85 
Marly-le-Roi, France), Clopidogrel (Santa Cruz Biotechnology, Heidelberg, Germany), MRS 86 
2179 (Tocris Bioscience, Bristol, United Kingdom), PAR4 antagonist pepducin p4pal-10 87 
(Polypeptide Laboratories, Strasbourg, France), PAR4 agonist peptide (AYPGKF-NH2, 88 
Bachem, Weil-am-Rhein, Germany), PAR4 control peptide (YAPGKF-NH2, Bachem) 89 
monoclonal anti-neutrophil Ly6G (Cedarlane, Tebu-bio, Le Perray en Yvelines, France), 90 
polyclonal anti-platelet CD41 (Bioss, Woburn, USA), monoclonal anti-viral HA (Santa Cruz 91 
Biotechnology, Heidelberg, Germany), monoclonal anti-IAV NP (gift from GF. 92 
Rimmelzwaan), monoclonal anti-p-Selectin FITC-conjugated (Emfret, Eibelstadt, Germany), 93 
monoclonal anti-CD41/61 PE-conjugated (Emfret); Vectastain® ABC kit (Vector 94 
Laboratories, Burlingame, USA), 3,3’-diaminobenzidine (DAB) peroxidase substrate (Vector 95 
Laboratories), ketamine/xylazine anesthesia (Virbac, Bayer HealthCare, Carros, France), 96 
May-Grünwald and Giemsa solutions (Merck, Darmstadt, Germany), hematoxylin and eosin 97 
solutions (Diapath, Martinengo, Italy), and enzyme-linked immunosorbent assay (ELISA) kits 98 
for mouse IL-6, IL-1β, MIP-2 (PromoCell GmbH, Heidelberg, Germany), IFN-DIFN-γ, 99 
RANTES (R&D Systems, Lille, France), serotonin (BlueGene, Shanghai, China), 100 
thromboxane B2 (TXB2; Elabscience, Wuhan, China) and sP-selectin (Qayee-Bio, Shanghai, 101 
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China). Total protein was evaluated by using the Coomassie Bradford Protein assay kit 102 
(Thermo Scientific, Massachusetts, USA).  103 
 104 
Mice  105 
Experiments were performed in accordance with the Guide for the Care and Use of 106 
Laboratory Animals of la Direction des Services Vétérinaires (DSV), the French regulations 107 
to which our animal care and protocol adhered. The license authority was issued by the DSV 108 
and Lyon University (accreditation 78-114). Protocols were approved by the Committee on 109 
Ethics of Animal Experiments of Lyon University (Permit BH2008-13).  110 
 111 
Female, 7-week-old BALB/c mice were used for H7N7 virus infections. Otherwise, 6-week-112 
old C57BL/6 female mice (Charles River Laboratories, Arbresle, France) and GPIIIa-/- mice 113 
or wild-type littermates on a C57BL/6 background were used in this study. For the latter, 114 
heterozygous mice were crossed, and WT and KO offspring (males and females) were used. 115 
Polymerase chain reaction of tail-tip genomic DNA was performed (12) to determine the 116 
absence or presence of the GPIIIa gene. Infection experiments were performed as previously 117 
described (13). Mice were anesthetized with ketamine/xylazine (42.5/5 mg/kg) and inoculated 118 
intranasally with IAV, in a volume of 20 µl. Eptifibatide was injected intraperitoneally (500 119 
µg/kg or 10 µg/200 µl per mouse of ~20 g body weight) every 3 days until the end of the 120 
experiment. MRS 2179 was dissolved in saline buffer and administered once intravenously 121 
(50 mg/kg) on day 0. Clopidogrel dissolved in saline buffer was injected intraperitoneally (30 122 
mg/kg) every day until the end of the experiment. For PAR4 stimulation experiments, mice 123 
were anesthetized every day for 3 days. On the first day, the anesthetized mice were infected 124 
intranasally in the presence or absence of PAR4-AP or control peptide (100 µg/mouse, in a 125 
volume of 20 µl). Intranasal peptide treatments were also repeated on days 2 and 3 after 126 
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infection. For PAR4 antagonist treatment, pepducin p4pal-10 was given intraperitoneally (0.5 127 
mg/kg) two days post-infection, and treatments were repeated on the next two days.  128 
 129 
Upon inoculation, the survival rates were followed. Alternatively, mice were sacrificed at 130 
prefixed time points to perform BAL or harvest lungs. ELISA was performed according to the 131 
manufacturers’ instructions. Virus titers were assessed as previously described (14). Lungs 132 
were also harvested for histology and immunohistochemistry as previously described (15).  133 
 134 
Evaluation of hemorrhagic foci by histopathological analysis 135 
Lungs from mice inoculated with A/PR/8/34 virus (250 PFU/mouse) with or without 136 
eptifibatide treatment were fixed in 10% neutral buffered formalin and embedded in paraffin. 137 
Then, 4–6 μm sections were cut and stained with hematoxylin and eosin (H&E) to evaluate 138 
histopathological changes. Staining was performed by incubation of the lung sections with 139 
Harris hematoxylin for 6 min, running tap water for 1 min, eosin Y for 10 min, 70% ethanol 140 
for 1 min, 95% ethanol for 1 min, 100% ethanol for 1 min and two rinses in 100% xylene for 141 
1 min. Histology and injury scoring were performed by a blinded investigator who analyzed 142 
the samples and determined the levels of injury according to a semiquantitative scoring 143 
system (counting inflammatory infiltration, vascular congestion, hemorrhage, fibrin deposits 144 
and epithelial cell apoptosis).   145 
 146 
Microscopy 147 
For ultrastructural analysis, lung tissues were cut into 1-mm3 pieces, fixed in 2% 148 
glutaraldehyde at 4°C, washed in 0.2 M cacodylate-HCl buffer containing 0.4 M saccharose 149 
and post-fixed in 0.3 M cacodylate-HCl buffer containing 2% osmium tetroxide for 1 hour. 150 
After dehydration in a graded alcohol series, tissue samples were impregnated with a 75% 151 
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Epon A/25% Epon B/1.7% DMP30 mixture. Tissue embedding entailed polymerization at 152 
60°C for 72 hours. Then, 70-nm sections were cut using an ultramicrotome (Leica 153 
Microsystems), mounted on 200-mesh copper grids coated with 1:1,000 polylysine, stabilized 154 
for 24 hours and contrasted with uranyl acetate/citrate. Sections were examined using a 155 
transmission electron microscope (JEOL 1400, Japan) at 80 kV equipped with an Orius 156 
SC600 camera (Gatan, France). Immunogold staining was performed using the anti-HA 157 
antibody followed by 10 nm gold-conjugated secondary antibody, as previously described 158 
(16). As a control of HA labelling, we used IAV particles that we recently purified (17). 159 
 160 
Fluorescence microscopy experiments 161 
Cells from the BAL were centrifuged at 1,800 rpm for 5 minutes at room temperature and 162 
suspended in phosphate buffer saline (PBS) at a concentration of 5x105/ml. Then, 100 µl of 163 
the solution was used to centrifuge the cells onto coverslips (1,000 rpm for 5 minutes), using a 164 
Shandon Cytospin 4 centrifuge. The slides were then dipped in a box containing methanol and 165 
kept at -20°C for fixation and permeabilization. After 10 minutes, cells were extensively 166 
washed with PBS to remove the fixative. Cells were then incubated with primary antibodies to 167 
CD41 and viral HA for 1 hour at room temperature. Revelation was performed using Alexa 168 
Fluo® (Life Technologies) secondary antibodies for 1 hour at room temperature. Cells were 169 
also counterstained with DAPI for 15 minutes at room temperature. Images were analyzed 170 
using a Leica TCS SP5 confocal system (Leica Microsystems). 171 
 172 
Evaluation of platelet and leukocyte numbers  173 
Platelets were counted using the Vet ABCTM Hematology Analyzer (SCIL) using the mouse 174 
smart card 7030. The automated cell counter differentiates mouse platelets based on their size 175 
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in multiple sample fluids. Leukocytes and neutrophils in the BAL were visualized by May-176 
Grünwald Giemsa stained cytospin preparations, as previously performed (13). 177 
  178 
Flow cytometry of blood platelets  179 
Blood was collected in ACD buffer by cardiac puncture. CD41-positive cells and platelet 180 
activation in whole blood were evaluated using FITC-conjugated P-selectin and PE-181 
conjugated CD41/CD61 antibodies, as previously described (18, 19).  182 
 183 
Statistical analysis 184 
The Kaplan-Meier test was used for survival rates. The Mann-Whitney test was used for two-185 
group comparisons of mean percentages in the flow cytometry experiments, lung virus titers, 186 
ELISA and total protein quantifications. One-way ANOVA for non-parametric measures 187 
(Kruskal-Wallis) was used for multiple-group comparisons in dose-responses or kinetics 188 
experiments. Dunn’s multiple comparison test was employed as a post hoc test using NI as a 189 
control. Probabilities *p< 0.05 was considered statistically significant.  190 
191 
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RESULTS 192 
 193 
Platelet recruitment to the lungs upon IAV infection 194 
Platelet recruitment to the lungs was first examined after infection of mice with a sublethal or 195 
a 50% lethal dose (LD50) of IAV A/PR/8/34. Immunohistochemistry of the lungs, using 196 
monoclonal antibodies for IAV nucleoprotein (NP) and CD41, was used to detect virus-197 
infected cells and platelets, respectively (Figure 1A). At both doses, many IAV-infected cells 198 
and marked platelet infiltrates were detected in the lungs of infected mice compared to 199 
uninfected mice. To confirm these results, platelet counts in the BAL of infected versus 200 
uninfected mice (sublethal dose or LD50) were assessed using a blood cell counter (Figure 201 
1B). In the BAL of infected mice, the platelet levels increased in a dose-dependent manner 202 
and were significantly higher than in those of uninfected mice, reaching 50×109 cells/L on 203 
day 6 post-inoculation (LD50). Differences were not significant upon infection with IAV at the 204 
sublethal dose.  205 
 206 
Viral proteins are present within platelets 207 
The presence of viral proteins was next determined in platelets from the BAL of infected 208 
mice. Platelets were identified by immunofluorescence as CD41 positive, DAPI-negative 209 
elements and IAV particles were detected using the viral anti-hemagglutinin (HA) antibody. 210 
In contrast to uninfected mice (NI), upon infection (LD50), CD41-positive DAPI-negative 211 
platelets stained positively for viral HA, demonstrating that platelets engulfed IAV particles, 212 
fragments of IAV or viral proteins in vivo (Figure 1C). CD41-negative/DAPI-positive cells 213 
were used as controls for antibody specificity. To confirm these results, immunogold labeling 214 
of ultrathin cryosections of lungs from uninfected or infected mice was performed using a 215 
specific anti-HA antibody. Examination of platelets clearly showed a positive and specific 216
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staining of viral HA proteins, which were located predominantly within platelet granule-like 217 
structures (Figure 1D, middle and upper right panels). The sparse staining could have been 218 
due to the procedure. Indeed, as a control, we used immunogold labelling of HA on highly 219 
purified A/PR/8/34 virus particles (17). Although virions of IAV contain approximatively 500 220 
molecules of HA per virion, few gold particles were observed (Figure 1D, lower right panel).  221 
 222 
Platelet activation and aggregation 223 
Upon activation, platelets become immobilized, secrete their granule content, and aggregate. 224 
Serotonin is released from platelet dense granules, and P-selectin is rapidly translocated from 225 
the alpha granules to the plasma membrane and shed. Thus, we next analyzed these responses 226 
in the lungs of infected mice (sublethal or LD50). Serotonin and soluble P-selectin (sP-227 
selectin) were measured in BAL and plasma, respectively, by ELISA (Figure 2A). Serotonin 228 
and sP-selectin were significantly higher in the fluid of infected mice compared to uninfected 229 
mice. Significant differences were only observed upon infection with IAV at LD50. 230 
Furthermore, exposure of P-selectin on the surface of platelets isolated from IAV-infected 231 
mice was increased compared to uninfected mice (Figure 2B, left panel). The average 232 
percentage of P-selectin-positive platelets reached 23% upon infection, versus 5% in 233 
uninfected mice (Figure 2B, right panel). Moreover, transmission electron microscopy 234 
showed that platelets in the lungs of influenza virus-infected mice were tightly packed, 235 
forming large extravascular aggregates with signs of shape change and some platelets were 236 
devoid of granules (Figure 2C). In contrast, in the lungs of uninfected mice, only a few 237 
isolated platelets were detected.  238 
 239 
Platelets contribute to influenza pathogenesis 240 
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Platelet GPIIIa+/- mice were intercrossed to generate wild-type (WT) and platelet GPIIIa-/- 241 
mice, which were then infected with IAV A/PR/8/34, and the survival rates were monitored. 242 
As shown in Figure 2D, compared to WT mice, GPIIIa-/- mice were significantly more 243 
resistant to IAV-induced death. 244 
 245 
Time course of platelet activation, IL1-E release and platelet binding to leukocytes 246 
Platelets were counted in the BAL of infected mice (LD50) at various times post-inoculation. 247 
Upon infection, platelet counts increased in a time-dependent manner (Figure 3A), peaked on 248 
day 3 and stayed elevated until day 8. Plasmatic sP-selectin significantly increased during the 249 
course of infection and plateaued on days 3-8 (Figure 3B). Increased IL1-E was also detected 250 
in the BAL and blood of infected mice but with different lags (Figure 3C-D). IL1-E was 251 
released in the BAL paralleled platelet activation, whereas IL1-E peaked in the blood on day 2 252 
post-inoculation and then rapidly decreased. Ultrastructural analysis of the lungs of 253 
A/PR/8/34-infected mice showed that platelet-leukocyte complexes formed in vivo. 254 
Neutrophils and monocytes were associated with platelet aggregates, although not all platelets 255 
adhered to leukocytes (Figure 3E).  256 
 257 
PAR4 promotes pathogenesis of IAV infection in a platelet-dependent pathway 258 
Mice were inoculated with a sublethal dose of IAV A/PR/8/34 and stimulated with 100 259 
µg/mouse of the PAR4 agonist peptide AYPGKF-NH2 (PAR4-AP) or the inactive control 260 
peptide YAPGKF-NH2 (Control-P). As expected, the content of serotonin and sP-selectin was 261 
increased in the BAL of infected mice treated with PAR4-AP compared to Control-P, 262 
indicating an increased level of platelet activation (Figure 4A). More interestingly, upon 263 
infection, mice treated with PAR4-AP displayed significantly higher mortality rates compared 264 
with mice treated with Control-P (Figure 4B). In contrast, treatment with PAR4-AP did not 265 
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affect the survival of uninfected mice. The effect was platelet dependent, as treatment of mice 266 
with eptifibatide, an antagonist of the GPIIbIIIa platelet receptor, abrogated the deleterious 267 
effect of PAR4-AP (Figure 4C), as did the platelet GPIIIa deficiency (Figure 4D). This 268 
indicated that PAR4-AP-induced platelet aggregation increased the severity of the IAV 269 
symptoms. No significant differences in lung virus titer were observed 3 or 6 days post-270 
inoculation between mice treated with PAR4-AP and those treated with Control-P (Figure 271 
4E). However, on day 6, treatment with PAR4-AP significantly increased total proteins in the 272 
BAL (Figure 4F). The response levels of IL-6, IL-1β and MIP-2 were also enhanced, while 273 
those of interferon (IFN)-γ, RANTES and KC were unaffected (Figure 5A). On day 3, no 274 
difference was observed. Thus, PAR4 activation promoted IAV-induced inflammation of the 275 
lungs at later time points post-infection. Similarly, staining of lung sections on day 6 revealed 276 
marked cellular infiltrates of leukocytes (HE) and neutrophils (Ly6G) in the lungs of PAR4-277 
AP-treated mice compared to controls (Figure 5B). Similar numbers of IAV-infected cells 278 
were detected by immunohistochemistry using an anti-NP antibody. No staining was observed 279 
in the lungs of uninfected control mice.  280 
 281 
PAR4 antagonism protects against influenza virus pathogenicity 282 
When mice were infected with IAV A/PR/8/34 (LD50), treatment with pepducin p4pal-10 283 
protected them from death (Figure 6A). Substantial protection was also observed against 284 
infection with an H3N2 virus, A/HK/1/68. The protection conferred by PAR4 antagonism 285 
correlated with the degree of inhibition of platelet activation. In the BAL of pepducin p4pal-286 
10-treated mice, decreased thromboxane B2 (TXB2), a specific marker of platelet activation, 287 
was observed (Figure 6B). In contrast, no difference in the mean lung virus titers was detected 288 
on day 3 or 6 after inoculation with IAV A/PR/8/34 (Figure 6C). However, treatment with 289 
pepducin p4pal-10 significantly reduced the recruitment of leukocytes (Figure 6D), including 290 
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neutrophils, in BAL on day 6. Total proteins (Figure 6E) and IL-6, IL-1β and MIP-2 (Figure 291 
6F) were also decreased. Consistent with those results, histopathology revealed that treatment 292 
with pepducin p4pal-10 reduced infiltration of inflammatory cells (HE), including neutrophils 293 
(Ly6G), in the lungs of infected mice (Figure 6G), while similar numbers of IAV-infected 294 
cells (NP) were detected by immunohistochemistry.  295 
 296 
The anti-platelet drug eptifibatide protects mice from lethal influenza infection 297 
Mice were inoculated with IAV A/PR/8/34 (LD50) and were treated or not with 500 µg/kg of 298 
eptifibatide every 3 days. This dosage is comparable to the lowest doses used clinically in 299 
humans (20-22). Eptifibatide treatment had a dramatic effect on lung infiltration by platelets: 300 
platelet aggregation was totally prevented, and only isolated platelets were observed (Figure 301 
7A). Furthermore, this effect was accompanied by decreases in TXB2 and sP-selectin in the 302 
fluid of infected mice compared to controls (Figure 7B), showing that inhibition of platelet 303 
aggregation also limited the extent of platelet activation. More importantly, treatment with 304 
eptifibatide improved the outcome of infection with A/PR/8/34 virus and prevented mortality 305 
of the mice (Figure 7C). Protection was also observed with other influenza strains. No effect 306 
of eptifibatide was observed in GPIIIa-/- mice (Figure 8A), showing the specificity of the drug. 307 
 308 
The protective effect of eptifibatide was independent of virus replication in lungs (Figure 8B) 309 
and IFN-Drelease in the BAL (Figure 8C). In contrast, it was correlated with decreased total 310 
proteins and levels of certain cytokines in the BAL of eptifibatide-treated mice (Figure 8D-E). 311 
Immunohistochemistry confirmed that treatment by eptifibatide prevented IAV-induced lung 312 
alveolar damage (HE) and neutrophil infiltration (Ly6G) but not viral replication (NP) on day 313 
6 post-infection (Figure 8F). This effect was not observed on day 2 (data not shown). 314 
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Treatment of infected mice with MRS 2179 and clopidogrel, which inhibits the ADP 315 
receptors P2Y1 and P2Y12, improved the outcome of IAV infection (Figure 8G). 316 
 317 
Eptifibatide treatment protects mice from lung injury induced by influenza  318 
Histopathological analyses of lung tissues were performed to evaluate the extent of 319 
hemorrhage after eptifibatide treatment. Mice were infected with A/PR/8/34 virus and treated 320 
with eptifibatide or vehicle, and lungs were then harvested 6 days post-inoculation for 321 
histopathology. In the infected group, lungs presented signs of congestion with infiltration of 322 
neutrophils and monocytes, interstitial and alveolar hemorrhages, as well as thrombosis 323 
(Figure 9A). Fibrin and erythrocyte-rich thrombi were observed in small vessels. Figure 9B 324 
summarizes the blinded semi-quantitative scoring of the different parameters. Eptifibatide 325 
markedly reduced the severity of pulmonary injury induced by influenza virus infections, and 326 
a marked reduction in neutrophil infiltration was observed. (Figure 9A-B). More importantly, 327 
almost no hemorrhage was detected in the lungs of infected mice treated with eptifibatide.  328 
329 
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DISCUSSION 330 
 331 
The present study shows that platelets play an active role in fueling the dysregulation of 332 
inflammation and promoting pathogenesis of influenza virus infections. Histological analysis 333 
of lungs provided evidence that platelets massively infiltrate the lungs of infected mice. 334 
Additionally, infiltrated platelets stained positive for viral HA, based on immunofluorescence 335 
staining of BAL and immunogold labeling of ultrathin cryosections of lungs. The technical 336 
limitation of the staining did not allow us to determine whether platelets engulfed the entire 337 
virions, only IAV fragments or antigens. However, because platelets incorporate influenza 338 
viruses in vitro (23), our results suggest that platelets recruited to the lungs most likely take up 339 
IAV particles in vivo as well. This could consist of a passive passage of particles through the 340 
open canalicular system, the tortuous invaginations of platelet surface membranes tunneling 341 
through the cytoplasm, in a manner similar to bacterial ingestion (24). Alternatively, uptake of 342 
IAVs may be compared to phagocytosis by macrophages and neutrophils, as previously 343 
observed for human immunodeficiency viruses (25).  344 
 345 
Ultrastructural analysis showed that features of platelets in the lungs of infected mice are 346 
those of aggregates of activated platelets: platelets were tightly stacked without interplatelet 347 
spaces, and some platelets were devoid of granules, suggesting that they had degranulated. 348 
Consistent with those observations, markers of platelet activation were detected in the BAL 349 
and plasma of infected mice. Thus, upon lethal IAV infection, platelets are activated in the 350 
lung and in the peripheral circulation. Our observations are consistent with the recent findings 351 
that influenza virus activates platelets through FcγRIIA signaling or thrombin generation (26). 352 
Also, thrombin triggers the release of serotonin and TXA2 from platelets, promotes P-selectin 353 
translocation to the platelet plasma membrane and activates the GPIIb/IIIa complex (27). 354 
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 355 
Platelets contribute to the host defense against bacterial infectious agents by limiting vascular 356 
lesions and inducing injury repair (28, 29). However, unbalanced platelet activation may have 357 
pathological consequences. In the IAV infection model used in this study, platelet activation 358 
and aggregation proved to be deleterious. PAR4 and GPIIIa are both key molecules in platelet 359 
function. PAR4 is strictly required for platelet activation in mice, while GPIIIa is required for 360 
platelet aggregation. First, mice deficient in GPIIIa were protected from lung injury and 361 
death. Furthermore, stimulation of PAR4 increased lung inflammation and the severity of 362 
IAV infection. In contrast, PAR4 antagonists protected mice from death. Our results indicate 363 
that PAR4 acts through platelet activation because the effect of PAR4-AP was abrogated 364 
when infected mice were treated with the platelet specific inhibitor eptifibatide (30), or when 365 
mice were deficient in platelet GPIIIa protein. Altogether, the data indicate that platelets 366 
regulate IAV pathogenesis. 367 
 368 
Interestingly, the observation by others that influenza virus activates platelets through 369 
thrombin generation (26) suggests that thrombin may also act in a deleterious manner against 370 
IAV infection. Thrombin mediates signal transduction mainly by activating PAR4 and PAR1 371 
(31, 32). Because mouse platelets do not express PAR1, thrombin-mediated platelet activation 372 
most likely occurs through PAR4 activation, but thrombin activation of PAR1 may also be 373 
involved in the pathogenesis of IAV infection. Indeed, we recently found that PAR1 signaling 374 
contributes to IAV pathogenicity in mice (33). In this context, PAR1 cooperates with 375 
plasminogen, which controls pathogenesis, via fibrinolysis (34). Thus, investigations into the 376 
role of hemostasis dysregulation may help better understand IAV pathogenesis (35-37). 377 
 378 
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In several models of injury, uncontrolled platelet activation drives deleterious inflammation 379 
(38). Activated platelets release an arsenal of potent pro-inflammatory molecules (39), which 380 
exacerbate neutrophil rolling, adhesion and recruitment (40-42). In addition, the physical 381 
interaction between platelets and neutrophils further contributes to neutrophil retention and 382 
activation (42). Because dysregulation of inflammation is a hallmark of severe influenza virus 383 
infections, it is likely that platelets have a pro-inflammatory effect with a key role in IAV 384 
pathogenesis. In our study, electron microscopy demonstrated the presence of neutrophil-385 
platelet complexes upon IAV infection. The anti-platelet molecule eptifibatide inhibited 386 
neutrophil recruitment into inflamed lungs (Figure 9). Thus, platelet interaction with 387 
neutrophils is likely to play a role during severe inflammation induced by influenza.  388 
 389 
Interestingly, the exacerbation of cytokine production induced by platelet activation was only 390 
observed at later time points after infection. Upon infection, the virus is recognized as foreign 391 
by highly conserved receptors known as pattern recognition receptors. Activation of these 392 
receptors results in the secretion of cytokines and chemokines, which corresponds to the early 393 
inflammatory response against IAV infection (35). Thus, the amplification and intensity of 394 
inflammation depends on the replicative capacity of the virus. When the response is tightly 395 
controlled, a resolution phase of inflammation is engaged at later time points post-infection, 396 
and this partly determines the duration of inflammation. Resolution of inflammation is largely 397 
influenced by the vascular endothelium (43). Upon injury of the latter, platelets are activated. 398 
Our data show coordinated platelet activation/aggregation and inflammatory responses at late 399 
time points post-infection, indicating that platelets may affect the recovery phase after 400 
infection and wound healing. In this scenario, extravasation of large numbers of platelets and 401 
leukocytes would be the basis of the defect in the resolution phase of the inflammation. Most 402 
18 
 
likely, this further promotes hemostasis dysregulation, such as fibrinolysis (18, 44) or PAR1 403 
activation (33, 45), fueling the vicious circle of inflammation (34, 35).  404 
 405 
Recurrent outbreaks of IAV that cause severe infections in humans have raised serious 406 
concerns about therapeutic strategies available for these pathogens. Current treatments that 407 
target viral proteins have a number of disadvantages, including the rapid development of 408 
resistant virus variants as a result of selective pressure (46, 47). Because targeting the host 409 
rather than the virus would not easily lead to resistance, drugs regulating inflammation are 410 
appealing as potential new therapeutics for IAV symptoms (13, 33, 34, 48). Here, we found 411 
that available anti-platelet drugs efficiently protected mice from IAV pathogenesis induced by 412 
several influenza strains. These results are consistent with other studies showing that aspirin, 413 
known to inhibit platelet activation, blocks IAV propagation via NF-kB inhibition (49). 414 
Altogether, these results suggest that anti-platelet drugs might be explored as new anti-415 
inflammatory treatments against severe influenza.  416 
 417 
418 
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FIGURE LEGENDS 577 
 578 
Figure 1: Upon IAV infection, platelets infiltrate the lungs, and IAV particles are 579 
observed in platelets. (A) Immunohistochemistry analysis of lungs from uninfected (NI) or 580 
infected mice inoculated with A/PR/8/34 virus, at a sublethal dose (75 pfu/mouse) or LD50 581 
(250 pfu/mouse; day 6 post-infection). Antibodies against the IAV nucleoprotein (NP) and 582 
CD41 were used to detect virus infected cells and platelets, respectively. The results are 583 
representative of three mice per group. (B) Platelet numbers in BAL were assessed using a 584 
Vet ABCTM Hematology Analyzer on day 6 post-inoculation of mock or IAV-infected mice. 585 
Data are presented as the means ± SEM of 4 mice per group, ** p<0.01 for LD50 vs. NI. (C) 586 
Immunofluorescence staining of viral particles in platelets from BAL was performed with 587 
anti-influenza HA antibody. Platelets were detected with anti-CD41 antibody, and nuclei were 588 
counterstained with DAPI. The merged images are shown on the right panel. CD41-negative 589 
cells from BAL were used as a negative control. (D) Immunogold labeling of ultrathin 590 
cryosections of lungs of uninfected (NI) or A/PR/8/34 virus-infected mice (LD50, 250 591 
pfu/mouse, day 6 post-infection) was performed using a specific anti-HA antibody. Black 592 
arrows indicate viral particles. Staining of a platelet-granule like structure is shown on the 593 
upper right panel. As a control for HA staining, electron microscopic immunogold labeling 594 
was performed on purified A/PR/8/34 viruses using the anti-HA antibody (lower right panel).  595 
 596 
Figure 2: Upon IAV infection, platelets are stimulated and contribute to influenza 597 
pathogenesis. (A) Serotonin and sP-selectin were measured by ELISA in the BAL and 598 
plasma of Mock (NI) or A/PR/8/34 virus-infected mice, respectively, on day 6 post-599 
inoculation (75 pfu/mouse, sublethal dose or 250 pfu/mouse, LD50). Data represent the means 600 
± SEM of 4 mice per group, * p<0.05 for LD50 vs. NI; ** p<0.01 for LD50 vs. NI. (B) Blood 601 
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samples from uninfected (NI) or infected mice were double-stained with anti-P-selectin and 602 
anti-CD41 antibody as a platelet identifier. The mean percentage ± SEM of activated platelets 603 
(CD41 and P-selectin-positive) from five mice per group is shown in the right panel, * p<0.05 604 
for LD50 vs. NI. (C) Ultrastructure analysis of platelets in the lungs of uninfected and infected 605 
mice (A/PR/8/34, 250 pfu/mouse, LD50). Note the aggregation of platelets in the lungs of 606 
infected mice along with their morphological changes (arrows) and the absence of granules in 607 
some of them, which reflects their degranulation (asterisks). Sections show platelet aggregates 608 
with an interstitial localization. (D) Survival of platelet GPIIIa-/- mice and WT littermates after 609 
infection with A/PR/8/34 virus at a LD50 (250 pfu/mouse, n=9-10 mice per group) or lethal 610 
dose (350 pfu/mouse n=6 mice per group); * p<0.05 and ** p<0.01, respectively. 611 
 612 
Figure 3: Platelet activation and inflammation. (A) Platelet numbers in BAL of A/PR/8/34 613 
virus infected mice (250 pfu/mouse, LD50) were assessed using a Vet ABCTM Hematology 614 
Analyzer, at the indicated time post-inoculation. The results are represented as the means ± 615 
SEM of 4 mice per group. On days 0 and 6, additional results from Figure 1B are included. 616 
(B-D) sP-selectin in the plasma (B), IL1-Ein the BAL (C) and IL1-Ein the plasma (D) of 617 
infected mice (A/PR/8/34, 250 pfu/mouse, LD50) were determined by ELISA at the indicated 618 
times. The results from panels B-D represent the means ± SEM of 4 mice per group. From A-619 
D: * p<0.05, ** p<0.01, *** p<0.001 for the indicated time vs. 0. (E) Ultrastructural analysis 620 
of platelets associated with leukocytes in the lungs of infected mice (A/PR/8/34, 250 621 
pfu/mouse, LD50). The star shows platelet aggregates that are not adherent to leukocytes. 622 
 623 
Figure 4: Effects of PAR4 activation on IAV pathogenicity, virus replication and 624 
inflammation. (A) Serotonin and sP-selectin were measured by ELISA in the BAL and 625 
plasma, respectively, of infected mice (A/PR/8/34, 75 pfu/mouse, sublethal dose) after 626 
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treatment with PAR4-AP or control peptide (Control-P) on day 6 post-inoculation. Columns 627 
represent the means ± SEM (n=4-5). ** p<0.01; * p<0.05. (B) Time course of IAV-induced 628 
death in mice in response to PAR4 stimulation. Mice were mock-infected or inoculated with 629 
A/PR/8/34virus (75 pfu/mouse, sublethal dose, n=18-19 mice per group; or 250 pfu/mouse, 630 
LD50, n=6-12 mice per group) and treated with either control peptide or PAR4-AP. * p<0.05; 631 
** p<0.01. (C) Time course of IAV-induced death in mice (A/PR/8/34virus) in response to 632 
PAR4 stimulation and after treatment or no treatment with eptifibatide (n=6-18 mice per 633 
group). * p<0.05 for PAR4-AP vs. control-P. A significant difference (p<0.01) was also found 634 
between groups treated with PAR-AP ± eptifibatide (not shown) (D) Time course of IAV-635 
induced death in WT (n=10 mice per group) and GPIIIa-/- mice (n=7-9 mice per group) in 636 
response to PAR4 stimulation (A/PR/8/34virus). The same mice were used in Figure 2D (250 637 
pfu/mouse, dose LD50). *** p<0.001 for PAR4-AP vs. control-P in WT mice. (E) Lung virus 638 
titers after infection of mice with A/PR/8/34 virus (sublethal dose) stimulated or not with 639 
PAR4-AP. (F) Total protein quantification in BAL of infected mice in response to PAR4 640 
stimulation. For E and F, the results represent the means ± SEM (n=3-5). ** p<0.01 for 641 
PAR4-AP vs. control-P. 642 
 643 
Figure 5: PAR4-AP increases lung inflammation upon A/PR/8/34 virus infection. (A) 644 
Cytokines in the BAL of infected mice (75 pfu/mouse, sublethal dose), treated with PAR4-AP 645 
or control peptide, were measured by ELISA 3 and 6 days after inoculation. Uninfected mice 646 
(NI) were used as control. The results represent the means ± SEM (n=3-5). * p<0.05, ** 647 
p<0.01 for PAR4-AP vs. control-P. (B) Histopathological analysis of lungs from uninfected 648 
mice or mice infected with a sublethal dose (75 pfu/mouse) of A/PR/8/34 virus after treatment 649 
with PAR4-AP or control peptide, on day 6 post-infection. Thin sections of lungs were 650 
stained with hematoxylin and eosin (HE). Note the marked infiltration of cells in the lungs of 651 
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infected mice stimulated with PAR4-AP. Immunohistochemistry used antibodies against 652 
Ly6G. Viral NP was used to detect neutrophils and virus-infected cells. Data are 653 
representative of three mice per group. 654 
 655 
Figure 6: PAR4 antagonist protects mice against IAV infection and deleterious lung 656 
inflammation. (A) IAV-induced pathogenesis in mice treated or not with the PAR4 657 
antagonist pepducin p4pal-10 (pepducin). Mice were inoculated with A/PR/8/34 virus (250 658 
pfu/mouse, LD50, n=13 mice per group) or A/HK/1/68 (100 pfu/mouse, LD50, n=12 mice per 659 
group) and treated with pepducin or saline. Survival was then monitored for 2 weeks. * 660 
p<0.05. (B) Thromboxane B2 (TXB2) was measured by ELISA in the BAL of infected mice 661 
(A/PR/8/34, 250 pfu/mouse, LD50) after treatment with pepducin or vehicle, on day 6 post-662 
inoculation. Data represent the mean ± SEM of 4-6 mice per group. (C) Lung virus titers after 663 
infection of mice with A/PR/8/34 virus (250 pfu/mouse, LD50) treated with pepducin or 664 
vehicle. The results represent the means ± SEM from 3 individual animals per group. (D) 665 
Relative leukocyte and neutrophil numbers in BAL from mice treated with pepducin or 666 
vehicle, determined by May-Grünwald-Giemsa staining 6 days after inoculation. Data 667 
represent the means ± SEM from 6 individual mice per group. (E, F) Total proteins and levels 668 
of cytokines were determined by ELISA in the BAL of infected mice (A/PR/8/34, 250 669 
pfu/mouse, LD50) after treatment with pepducin or vehicle, on day 6 post-inoculation. The 670 
results represent the means ± SEM of 6 mice per group. (G) Histopathological analysis of 671 
lungs from mice infected with A/PR/8/34 virus (250 pfu/mouse, LD50) after treatment with 672 
pepducin or vehicle, on day 6 post-infection. Lung sections were stained with hematoxylin 673 
and eosin (HE). Immunohistochemistry using antibodies against Ly6G, viral NP was used to 674 
detect neutrophils and virus-infected cells. Data are representative of three mice per group. 675 
(B-F). * p<0.05, ** p<0.01 for pepducin vs. saline. 676 
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 677 
Figure 7: Eptifibatide protects mice against IAV infection, independently of the strain. 678 
(A) Ultrastructural analysis of platelets in the lungs of infected mice (A/PR/8/34, 250 679 
pfu/mouse, LD50), treated or not with eptifibatide, was performed by transmission electron 680 
microscopy. Note the aggregation of platelets in the lungs of infected mice, and their 681 
disaggregation after treatment of mice with eptifibatide. Sections show platelet aggregates 682 
with an interstitial localization. (B) Thromboxane B2 (TXB2) was measured by ELISA in the 683 
BAL of infected mice (A/NL/602/09, 30,000 pfu/mouse LD50) after treatment with 684 
eptifibatide or vehicle. The results represent the means ± SEM of 3-5 mice per group. sP-685 
selectin was measured by ELISA in the plasma of A/PR/8/34 virus-infected mice (250 686 
pfu/mouse, LD50) that were treated or not with eptifibatide, on day 6 post-inoculation. Data 687 
represent the means ± SEM of 4 mice per group. * p<0.05 for pepducin vs. saline. (C) 688 
Survival of mice treated with eptifibatide or vehicle after infection with IAV A/PR/8/34 689 
(n=13 mice per group, 250 pfu/mouse), A/NL/602/09 (n=9-12 mice per group, 30,000 690 
pfu/mouse) or A/HK/1/68 (n=12 mice per group, 100 pfu/mouse) at their respective LD50 691 
values. A/FPV/Bratislava/79 was used at 5 Pfu/mouse (n=6-7 mice per group). * p<0.05, ** 692 
p<0.01 for pepducin vs. saline. 693 
 694 
Figure 8: Eptifibatide treatment prevents severe inflammation during influenza virus 695 
infections. (A) Survival of GPIIIa-/- (n=5 mice/group) and WT mice (n=12 mice/group) after 696 
infection with IAV A/PR/8/34 (300 pfu/mouse) and treatment or no treatment with 697 
eptifibatide. * p<0.05 for eptifibatide vs. saline. (B) Lung virus titers after infection of mice 698 
with the A/NL/602/09 virus (30,000 pfu/mouse, LD50) treated with eptifibatide or vehicle. 699 
Data represent the means ± SEM from 3 individual animals per group. (C) IFN-Dwas 700 
measured by ELISA in the BAL of infected mice (A/PR/8/34, 250 pfu/mice) after treatment 701 
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with eptifibatide or vehicle. The results represent the means ± SEM of 4 mice per group. (D, 702 
E) Total proteins and levels of cytokines were determined by ELISA in the BAL of infected 703 
mice (30 000 pfu/mouse, A/NL/602/09, LD50) after treatment with eptifibatide or vehicle. The 704 
results represent the means ± SEM of 3-5 mice per group. * p<0.05, ** p<0.01 for eptifibatide 705 
vs. saline. (F) Histopathological analysis of lungs from mice infected with A/NL/602/09 virus 706 
(30 000 pfu/mouse, LD50) after treatment with eptifibatide or vehicle, on day 6 post-infection. 707 
Lung sections were stained with hematoxylin and eosin (HE). Immunohistochemistry using 708 
antibodies against Ly6G and viral NP was used to detect neutrophils and virus-infected cells. 709 
Data are representative of three mice per group. (G) Survival of mice treated with MRS 2179, 710 
clopidogrel or vehicle after infection with IAV A/PR/8/34 (250 pfu/mouse; n=12 mice per 711 
group). ** p<0.01 for MRS 2179 vs. saline; * p<0.05 for clopidogrel vs. saline. 712 
 713 
Figure 9: Histopathological analysis of lungs from infected mice after treatment with 714 
eptifibatide. (A) Histopathological analysis of lungs obtained from mice inoculated with 715 
A/PR/8/34 virus (250 PFU/mouse) and treated or not with eptifibatide. In the infected group, 716 
note the extended areas with interstitial and peribronchial inflammation and interstitial and 717 
alveolar hemorrhage. In the infected group treated with eptifibatide, note the limited areas 718 
with slight peribronchial inflammation but no major hemorrhage. (B) Blinded 719 
semiquantitative scoring of inflammatory infiltration, vascular congestion, hemorrhage, fibrin 720 
deposits and epithelial cell apoptosis in the lungs of infected mice treated or not with 721 
eptifibatide. All lung fields were examined (50x) for each sample. The scoring was performed 722 
as follows: 0=no lesion, x=mild, xx=moderate, xxx=severe.  723 
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